Raloxifene, tamoxifen and vascular tone

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 8, 2007, Pages 809-813

  Leung, Fung Ping ^a   Tsang, Suk Ying ^a   Wong, Chi Ming ^a   Yung, Lai Ming ^a   Chan, Yau Chi ^a   Leung, Hok Sum ^a   Yao, Xiaoqiang ^a   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Endothelial function; Raloxifene; Sex hormone; Tamoxifen; Vascular tone

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; FULVESTRANT; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; NITRIC OXIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ATHEROGENESIS; BLOOD VESSEL TONE; BREAST CANCER; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CHO CELL; CORONARY ARTERY BLOOD FLOW; DOG; DRUG MECHANISM; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MENOPAUSAL SYNDROME; MOUSE STRAIN; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; RAT STRAIN; REVIEW; STROKE; UTERUS CANCER;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; COLLATERAL CIRCULATION; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NITRIC OXIDE; PULMONARY CIRCULATION; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VASODILATION;

EID: 34347338584     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04684.x     Document Type: Review

References (70)

1. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: Effects of raloxifene administration. J. Clin. Endocrinol. Metab. 2003 88 : 2135 40.
2. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc. Drugs Ther. 2003 17 : 319 23.
3. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J. Clin. Endocrinol. Metab. 2000 85 : 2966 9.
4. Simoncini T, De Caterina R, Genazzani AR. Selective estrogen receptor modulators: Different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J. Clin. Endocrinol. Metab. 1999 84 : 815 18.
5. Saitta A, Altavilla D, Cucinotta D et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2001 21 : 1512 19.
6. Kublickiene K, Svedas E, Landgren BM et al. Small artery endothelial dysfunction in postmenopausal women. In vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. 2005 90 : 6113 22.
7. Ogita H, Node K, Asanuma H et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J. Am. Coll. Cardiol. 2002 40 : 998 1005.
8. Ogita H, Node K, Liao Y et al. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 2004 43 : 237 42.
9. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am. J. Obstet. Gynecol. 2000 182 : 521 8.
10. Gaynor JS, Monnet E, Selzman C et al. The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J. Vet. Pharmacol. Ther. 2000 23 : 175 9.
11. Leitzbach D, Weckler N, Madajka M, Malinski T, Wiemer G, Linz W. Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats. Arzneimittelforschung 2005 55 : 86 92.
12. Wong CM, Yao X, Au CL et al. Raloxifene prevents endothelial function in aging ovariectomized female rats. Vasc. Pharmacol. 2006 44 : 290 8.
13. Pavo I, Laszlo F, Morschl E et al. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. Eur. J. Pharmacol. 2000 410 : 101 4.
14. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur. J. Pharmacol. 2002 434 : 141 9.
15. Wassmann S, Laufs U, Stamenkovic D et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002 105 : 2083 91.
16. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002 105 : 1368 73.
17. Hisamoto K, Ohmichi M, Kanda Y et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J. Biol. Chem. 2001 276 : 47 642 9.
18. Muller-Delp JM, Lubahn DB, Nichol KE et al. Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-α-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H2150 7.
19. Sumi D, Ignarro LJ. Estrogen-related receptor α1 up-regulates endothelial nitric oxide synthase expression. Proc. Natl Acad. Sci. USA 2003 100 : 14 451 6.
20. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: Implication of COX-1 and COX-2. Menopause 2004 11 : 430 7.
21. Oviedo PJ, Hermenegildo C, Tarin JJ, Cano A. Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2. Fertil. Steril. 2005 83 : 1822 9.
22. Santos RL, Abreu GR, Bissoli NS, Moyses MR. Endothelial mediators of 17β-estradiol-induced coronary vasodilation in the isolated rat heart. Braz. J. Med. Biol. Res. 2004 37 : 569 75.
23. Wenger NK. Cardiovascular effects of raloxifene: The potential for cardiovascular protection in women. Diabetes Obes. Metab. 2002 4 : 166 76.
24. Tsang SY, Yao X, Essin K et al. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 2004 35 : 1709 14.
25. Zhang L, Kosaka H. Sex-specific acute effect of estrogen on endothelium-derived contracting factor in the renal artery of hypertensive Dahl rats. J. Hypertens. 2002 20 : 237 46.
26. Leung FP, Yao X, Lau CW, Ko WH, Lu L, Huang Y. Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx. Am. J. Physiol. Renal Physiol. 2005 289 : F137 44.
27. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999 100 : 1095 101.
28. Bracamonte MP, Rud KS, Miller VM. Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J. Cardiovasc. Pharmacol. 2002 39 : 704 13.
29. McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J. Appl. Physiol. 1973 35 : 459 62.
30. Gonzales RJ, Walker BR, Kanagy NL. 17β-Estradiol increases nitric oxide-dependent dilation in rat pulmonary arteries and thoracic aorta. Am. J. Physiol. Lung Cell Mol. Physiol. 2001 280 : L555 64.
31. Chan Y, Leung F, Yao X, Lau C, Vanhoutte PM, Huang Y. Raloxifene relaxes rat pulmonary arteries and veins. Roles of gender, endothelium and antagonism of Ca2+ influx. J. Pharmacol. Exp. Ther. 2005 312 : 1266 71.
32. Fisher B, Bryant J, Dignam JJ et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. 2002 20 : 4141 9.
33. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995 311 : 977 80.
34. Simon T, Boutouyrie P, Simon JM et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation 2002 106 : 2925 9.
35. Stamatelopoulos KS, Lekakis JP, Poulakaki NA et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am. Heart J. 2004 147 : 1093 9.
36. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001 103 : 1497 502.
37. Chlebowski RT, Col N, Winer EP et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol. 2002 20 : 3328 43.
38. Tsang SY, Yao X, Chan FL et al. Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. Hypertension 2004 44 : 78 82.
39. Thorin E, Pham-Dang M, Clement R, Mercier I, Calderone A. Hyper-reactivity of cerebral arteries from ovariectomized rats. Therapeutic benefit of tamoxifen. Br. J. Pharmacol. 2003 140 : 1187 92.
40. Song J, Standley PR, Zhang F et al. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J. Pharmacol. Exp. Ther. 1996 277 : 1444 53.
41. Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J. Pharmacol. Exp. Ther. 2000 295 : 519 23.
42. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J. Cardiovasc. Pharmacol. 2001 38 : 657 65.
43. Wickman G, Vollrath B. Effects of tamoxifen on oxyhemoglobin-induced cerebral vasoconstriction. Eur. J. Pharmacol. 2000 390 : 181 4.
44. Park S, Kim B, Kim J et al. Tamoxifen induces vasorelaxation via inhibition of mitogen-activated protein kinase in rat aortic smooth muscle. J. Vet. Med. Sci. 2003 65 : 1155 60.
45. Welsh DG, Nelson MT, Eckman DM, Brayden JE. Swelling-activated cation channels mediate depolarization of rat cerebrovascular smooth muscle by hyposmolarity and intravascular pressure. J. Physiol. 2000 527 : 139 48.
46. Dick GM, Rossow CF, Smirnov S, Horowitz B, Sanders KM. Tamoxifen activates smooth muscle BK channels through the regulatory β1 subunit. J. Biol. Chem. 2001 276 : 34 594 9.
47. Tsang SY, Yao X, Wong CM, Chan FL, Chen ZY, Huang Y. Differential regulation of K+ and Ca2+ channel gene expression by chronic treatment with estrogen and tamoxifen in rat aorta. Eur. J. Pharmacol. 2004 483 : 155 62.
48. Brenner R, Perez GJ, Bonev AD et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature 2000 407 : 870 6.
49. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention Trial. Lancet 1998 352 : 98 101.
50. Takahashi Y, Zhu H, Yoshimoto T. Essential roles of lipoxygenases in LDL oxidation and development of atherosclerosis. Antioxid. Redox. Signal. 2005 7 : 425 31.
51. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003 10 : 142 6.
52. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCl). Atherosclerosis 1996 126 : 65 75.
53. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997 337 : 1641 7.
54. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998 279 : 1445 51.
55. Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J. Clin. Endocrinol. Metab. 2000 85 : 214 18.
56. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Knadler MP, Christiansen C. Raloxifene reduces atherosclerosis: Studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin. Endocrinol. 2000 52 : 225 33.
57. Castelo-Branco C, Sanjuan A, Casals E et al. Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits. J. Obstet. Gynaecol. 2004 24 : 47 51.
58. Bjarnason NH, Haarbo J, Byrjalsen I, Alexandersen P, Kauffman RF, Christiansen C. Raloxifene and estrogen reduces progression of advanced atherosclerosis: A study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis 2001 154 : 97 102.
59. Kauffman RF, Bean JS, Fahey KJ, Cullinan GJ, Cox DA, Bensch WR. Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. J. Cardiovasc. Pharmacol. 2000 36 : 459 65.
60. Takahashi K, Ohmichi M, Yoshida M et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J. Endocrinol. 2003 178 : 319 29.
61. Silfani TN, Fulton CT, Wildroundt ML, Stallone JN, Freeman EJ. Estrogen or selective estrogen receptor modulators (SERMs) inhibit Ang II-induced arachidonic acid (AA) release and growth in vascular smooth muscle cells (VSMC). FASEB J. 2001 14 : A456 (Abstract).
62. Mori-Abe A, Tsutsumi S, Takahashi K et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 2003 178 : 417 26.
63. Mitsuhashi T, Morris Jr. RC, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Invest. 1991 87 : 1889 95.
64. Somjen D, Kohen F, Amir-Zaltsman Y, Knoll E, Stern N. Vitamin D analogs modulate the action of gonadal steroids in human vascular cells in vitro. Am. J. Hypertens. 2000 13 : 396 403.
65. Rebsamen MC, Sun J, Norman AW, Liao JK. 1α,25-Dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ. Res. 2002 91 : 17 24.
66. Somjen D, Weisman Y, Kohen F et al. 25-Hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005 111 : 1666 71.
67. Tritos NA, Goepfert L, Kissinger KV, Katsimaglis G, Manning WJ, Danias PG. Effect of raloxifene on aortic elasticity in healthy postmenopausal women. Am. Heart J. 2005 150 : 1212.
68. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 33.
69. Wickerham DL, Tan-Chiu E. Breast cancer chemoprevention: Current status and future directions. Semin. Oncol. 2001 28 : 253 9.
70. Mosca L, Barrett-Connor E, Wenger NK et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 2001 88 : 392 5.